Core Insights - Fosun Pharma reported a revenue of 29.393 billion yuan and a net profit of 2.523 billion yuan for the first three quarters of 2025, marking a year-on-year growth of 25.5% [1] - The revenue from innovative drugs reached over 6.7 billion yuan, reflecting an 18.09% increase year-on-year, indicating an ongoing optimization of the revenue structure [1] - The company is focusing on lean operations, cost reduction, and asset lightening to enhance its asset and financial structure, with net cash flow from operating activities amounting to 3.382 billion yuan, a 13.23% increase year-on-year [1] R&D Investment - Fosun Pharma's R&D investment totaled 3.998 billion yuan in the first three quarters of 2025, a 2.12% increase year-on-year, with R&D expenses at 2.730 billion yuan [2] - In Q3, R&D expenses reached 1.013 billion yuan, up 28.81% year-on-year, primarily directed towards innovative platforms including nuclear medicine and cell therapy [2] - The company's self-developed PD-1 inhibitor, Hanshuozhuang, is progressing well in clinical trials, with a Phase III study for gastric cancer achieving its primary endpoint, supporting early market application [2] Strategic Developments - Fosun Pharma completed its A-share and H-share buyback plans for 2025 and launched stock option incentive plans to enhance long-term incentive mechanisms [3] - In August 2025, the company successfully issued a 1 billion yuan, 2-year medium-term technology innovation bond, becoming the first private pharmaceutical company to issue such bonds following a regulatory announcement [3]

Core Viewpoint - Fosun Pharma plans to spin off its subsidiary Fosun Antigen, which operates in the vaccine sector, for a listing on the Hong Kong Stock Exchange to enhance corporate governance and sustainable development, ultimately maximizing shareholder value [1] Group 1 - The proposed spin-off aims to improve the governance level and sustainable development of Fosun Antigen, which is a platform for the group's vaccine business [1] - The spin-off is expected to broaden financing channels and enhance market competitiveness for Fosun Antigen [1] - This move will further deepen the group's layout in the vaccine field, strengthening the overall competitiveness of the group [1]

Core Viewpoint - Fosun Pharma (02196.HK) announced its intention to invest RMB 100 million as a limited partner (LP) in a target fund, which will focus on strategic emerging sectors such as chemical innovative drugs, biopharmaceuticals (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology [1] Group 1 - The company will collaborate with 11 other investors to establish the target fund [1] - The investment is scheduled to be made on October 28, 2025 [1] - The target fund aims to invest in enterprises within specific strategic emerging sectors [1]

Core Insights - Fosun Pharma reported a revenue of 29,393,385,360.91 yuan for the first three quarters of 2025, representing a year-on-year decline of 4.91% [1] - The net profit attributable to shareholders of the listed company was 2,523,293,508.22 yuan, showing a year-on-year increase of 25.50% [1] Financial Performance - Revenue for the first three quarters of 2025: 29.39 billion yuan, down 4.91% year-on-year [1] - Net profit for the same period: 2.52 billion yuan, up 25.50% year-on-year [1]

北京商报讯（记者 王寅浩 宋雨盈）10月28日，复星医药发布2025年第三季度报告，第三季度实现营业 收入98.79亿元，同比下降5.46%；归属于上市公司股东的净利润为8.21亿元，同比增长4.52%。2025年 前三季度实现营业收入293.93亿元，同比下降4.91%；归属于上市公司股东的净利润为25.23亿元，同比 增长25.5%。 ...

Core Viewpoint - Fosun Pharma (02196.HK) announced a partnership agreement to establish a target fund with an investment of RMB 100 million, focusing on strategic emerging sectors such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology [1] Group 1 - The company will act as a Limited Partner (LP) in the investment, contributing RMB 100 million [1] - The target fund aims to invest in enterprises within strategic emerging sectors [1] - The investment will cover various fields including chemical innovative drugs, biological drugs, high-end medical devices, traditional Chinese medicine, and synthetic biology [1]

Core Viewpoint - Fosun Pharma (600196)(02196) announced its participation as a limited partner (LP) in a target fund with a cash investment of RMB 100 million, aimed at investing in strategic emerging sectors such as chemical innovative drugs, biopharmaceuticals (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology [1] Group 1 - The investment involves collaboration with 11 other investors under a partnership agreement signed on October 28, 2025 [1] - The target fund will focus on leveraging the strengths of both Fosun Pharma and China Resources Pharmaceutical in the health sector [1] - The investment strategy aligns with local industrial policies and geographical advantages in Chengdu, aiming to expand the company's presence in innovative drugs, biopharmaceuticals, high-end medical devices, synthetic biology, and other strategic emerging fields [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 擬籌劃控股子公司分拆上市的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 * 僅供識別 证券代码：600196 股票简称：复星医药 编号：临 2025-166 上海复星医药（集团）股份有限公司 中國，上海 2025 年1 0 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 參與設立私募股權投資基金的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 0 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年第三季度業績說明會預告公告》，僅供參閱。 承董事會命 陳玉卿 中國，上海 2025 年1 0 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 上海復星醫藥（集團）股份有限公司 董事長 * 僅 ...